ZBIO:NSD-Zenas BioPharma, Inc. Common Stock (USD)

COMMON STOCK | Trading--Inverse Equity |

Last Closing

USD 8.43

Change

+0.83 (+10.92)%

Market Cap

N/A

Volume

0.16M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-02 )

Largest Industry Peers for Trading--Inverse Equity

Symbol Name Price(Change) Market Cap
SQQQ ProShares UltraPro Short QQQ

-0.84 (-2.24%)

USD 2.21B
BIS ProShares UltraShort Nasdaq Bi..

-0.73 (-3.71%)

USD 3.28M

ETFs Containing ZBIO

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Inverse Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.93% 33% F 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.93% 33% F 76% C+
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -15.87% 100% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.87% 100% F 29% F
Average Annual (5 Year Horizon)  
Capital Gain 4.81% 33% F 54% F
Dividend Return 4.81% 33% F 51% F
Total Return N/A 33% F N/A F
Risk Return Profile  
Volatility (Standard Deviation) 21.01% 100% F 75% C
Risk Adjusted Return 22.89% 100% F 57% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.